Otonomy Revenue and Competitors
Estimated Revenue & Valuation
- Otonomy's estimated annual revenue is currently $178k per year.
- Otonomy's estimated revenue per employee is $10,471
- Otonomy's total funding is $458M.
- Otonomy's current valuation is $116.7M. (January 2022)
Employee Data
- Otonomy has 17 Employees.
- Otonomy grew their employee count by -60% last year.
Otonomy Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Otonomy?
Otonomy is a clinical stage biopharmaceutical company developing novel drug therapies for disorders of the inner and middle ear. This field represents a large opportunity as there are no approved drug treatments for the nearly 30 million Americans facing debilitating hearing and balance disorders such as Ménière's disease, sudden sensorineural hearing loss, noise-induced hearing loss, age-related hearing impairment, and tinnitus. Additionally, new therapies are required for otitis media since resistance to oral antibiotics is increasing and short-acting locally administered drugs present significant compliance challenges. Otonomy is working in partnership with leading experts in the field of otology to bring new drug therapies to patients suffering with these conditions.
keywords:Biotechnology
$458M
Total Funding
17
Number of Employees
$178k
Revenue (est)
-60%
Employee Growth %
$116.7M
Valuation
N/A
Accelerator
Otonomy's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Otology Sales Specialist/ Hospital Account Manager | Reveal Email/Phone |
2 | HR Manager | Reveal Email/Phone |
3 | Director, Clinical Operations and Drug Safety | Reveal Email/Phone |
4 | Senior Accountant | Reveal Email/Phone |
5 | VP, Regulatory Affairs & QA | Reveal Email/Phone |
6 | Research Scientist | Reveal Email/Phone |
7 | Chief Scientific Officer | Reveal Email/Phone |
8 | Chief Technical Officer | Reveal Email/Phone |
9 | Senior Director Clinical Operations | Reveal Email/Phone |
10 | Chief Financial & Business Officer | Reveal Email/Phone |
Otonomy News
Development-stage biopharmaceutical company Otonomy Inc. shares said a drug candidate showed promise in a mid-stage trial involving patients...
Otonomy (NASDAQ:OTIC) on Wednesday announced what it deemed to be positive results from its phase 2a trial of its formulation OTO-413 in...
Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 ... SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Otonomy,...
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 6,288,890 shares of its common stock at a price to th ...
San Diego drug developer Otonomy Inc. announced Jan 12 the closing of its $115 million public offering of stock. The previously announced public offering included 5,750,000 shares of its common stock, and an additional 750,000 shares (sold pursuant to the underwriter’s full exercise of their op ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.8M | 17 | 6% | $21.4M |
#2 | $3.6M | 17 | N/A | N/A |
#3 | $1.5M | 17 | N/A | N/A |
#4 | $1.5M | 17 | N/A | N/A |
#5 | $1.5M | 17 | N/A | N/A |